Location History:
- Telangana, IN (2021)
- Hyderabad, IN (2023)
Company Filing History:
Years Active: 2021-2023
Title: Deviprasanna Chakka: A Pioneer in Pneumococcal Vaccine Innovation
Introduction
Deviprasanna Chakka is an accomplished inventor based in Telangana, India, recognized for her contributions to the field of vaccine development. With a focus on pneumococcal vaccines, she has secured two patents that delve into innovative methods for enhancing vaccine formulations. Her work exemplifies the merging of scientific research with practical applications aimed at improving public health.
Latest Patents
Deviprasanna Chakka's most recent patents include groundbreaking formulations aimed at combating pneumococcal diseases. One of her significant inventions is a multivalent pneumococcal vaccine composition that includes polysaccharide-protein conjugates. This innovative formulation comprises capsular pneumococcal polysaccharide serotypes that are each individually conjugated to carrier proteins. By utilizing these polysaccharide-protein conjugates, the vaccine aims to enhance the immune response. Additional components of her vaccine compositions may include a variety of ingredients such as pharmaceutically acceptable carriers, diluents, buffers, preservatives, stabilizers, adjuvants, and lyophilization excipients. Moreover, she has developed a method for the high-level production of CRM (a critical protein) using an engineered strain with an increased copy number of the CRM gene, significantly improving the yield while ensuring the media is free from animal-derived components.
Career Highlights
Deviprasanna works at Biological E Limited, a leading biopharmaceutical company known for its advancements in vaccine and therapeutic product development. Her position at such a reputable company underscores her expertise and the value of her inventive contributions to the field.
Collaborations
Throughout her career, Deviprasanna has collaborated with notable colleagues, including Ramesh Venkat Matur and Rajan Sriraman. These collaborations reflect a synergistic approach to innovation in vaccine research, demonstrating the strength of teamwork in advancing scientific discoveries and addressing global health challenges.
Conclusion
Deviprasanna Chakka's patents represent significant advancements in pneumococcal vaccine technology. Her dedication to innovation within the biopharmaceutical sector, particularly through her work at Biological E Limited and her collaborations, highlights her crucial role in enhancing public health solutions. As she continues to develop effective vaccine compositions, her contributions are poised to make a lasting impact on disease prevention and health improvement efforts globally.